H.B. Fuller Company

Despite a pronounced Stage 4 decline and active downtrend, mean-reversion eligibility opens a tactical long opportunity. Price is oversold and trading near the early-2025 cycle low support zone, yet remains below declining EMAs. The medium-term bias is Bullish under mean-reversion permission, while short-term timing is neutral pending support absorption. Execution is deferred: stalk around the support region, awaiting confirmation of pullback absorption. Primary risks include a decisive breakdown below support and a false rebound reclaiming the EMAs without real continuation.

• ↑AMS acquisition to add ~$55M annual revenue in medical adhesives
• ↑Q2 2026 revenue $667M up 5.8% YoY; organic growth 2.6%
• ↓Volume decline of 6.6% in HHC segment signals weak end-market demand